Gastroesophageal Junction Carcinoma — Trials

Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

707 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 231
Recruiting: 126
Ph III recruiting: 18
Growth YoY: +44.2%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05041153	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	active not recruiting	Early Phase 1	15	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials

Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials